Insurance firm reverses decision after denying teen brain surgery
2026-05-28
Insurance bureaucracy, not medicine, set the ceiling on one teenager’s care. Daily epileptic seizures had persisted despite multiple antiseizure drugs, a classic profile for so‑called drug‑resistant epilepsy, in which abnormal cortical electrical activity ignores pharmacologic blockade and keeps firing.
Deep brain stimulation, a neuromodulation procedure that targets circuits such as the thalamus with implanted electrodes and a pulse generator, offered a final option. Surgeons believed the odds justified the risk. Her family did too. Anthem Blue Cross Blue Shield did not. The company labeled the procedure for children as experimental and refused to authorize payment, effectively nullifying the clinical recommendation.
Media exposure, not a new randomized controlled trial, altered that stance. After NBC News questioned the denial and highlighted the teen’s case, Anthem revised its medical policy language to include coverage of deep brain stimulation for a defined subset of pediatric patients with refractory epilepsy. The change exposes a blunt reality: access to advanced neurotechnology can depend less on electroencephalography findings or seizure frequency than on whether a coverage decision happens to attract a spotlight.
Loading...
